• CMS implements single reimbursement rate of US$127.14 per square centimetre for outpatient skin substitutes, positioning Symphony well for adoption
• Myriad study finds wounds treated achieved tissue coverage in median of 22.5 days, often with just one application and no complications
• FY26 full year guidance reaffirmed, expected to be at upper end of total revenue range of NZ$92-100 million and normalised EBITDA of NZ$5-8 million

Aroa Biosurgery Limited (ASX: ARX) has provided an update on key focus areas of its business. Regarding Symphony, the company noted that the US Centers for Medicaid and Medicare Services (CMS) has implemented a single reimbursement rate of US$127.14 per square centimetre for outpatient skin substitutes, leaving Symphony well positioned for outpatient adoption. AROA's Symphony Randomised Control Trial (RCT), designed to assess efficacy in treating diabetic foot ulcers, has concluded and is expected to be published in FY27. For Myriad, a study was published assessing its effectiveness in trauma procedures, finding that wounds treated with Myriad achieved full vascularized tissue coverage in a median of 22.5 days, often with just one product application and no device-related complications. The study also included a literature review indicating Myriad's outcomes were equivalent to or better than reported outcomes of alternative bioscaffolds. AROA reaffirmed its FY26 full year guidance, expecting its results to fall at the upper end of the total revenue guidance range of NZ$92-100 million and normalised EBITDA of NZ$5-8 million.

AROA expects its full year FY26 results to fall at the upper end of the total revenue guidance range of NZ$92-100 million and normalised EBITDA of NZ$5-8 million.